Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 342

1.

Recent advances in the treatment of acute lymphoblastic leukemia.

Rafei H, Kantarjian HM, Jabbour EJ.

Leuk Lymphoma. 2019 May 16:1-16. doi: 10.1080/10428194.2019.1605071. [Epub ahead of print]

PMID:
31092071
2.

Dasatinib as an investigational drug for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults.

Brattås MK, Reikvam H, Tvedt THA, Bruserud Ø.

Expert Opin Investig Drugs. 2019 May;28(5):411-420. doi: 10.1080/13543784.2019.1597052. Epub 2019 Apr 5. Review.

PMID:
30916583
3.

Primary Cutaneous T-Cell Lymphoblastic Lymphoma: Case Report and Literature Review.

Khurana S, Beltran M, Jiang L, Ayala E, Roy V.

Case Rep Hematol. 2019 Feb 20;2019:3540487. doi: 10.1155/2019/3540487. eCollection 2019.

4.

Philadelphia chromosome-like acute lymphoblastic leukemia: A review of the genetic basis, clinical features, and therapeutic options.

Khan M, Siddiqi R, Tran TH.

Semin Hematol. 2018 Oct;55(4):235-241. doi: 10.1053/j.seminhematol.2018.05.001. Epub 2018 May 29. Review.

PMID:
30502852
5.

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study.

Jabbour E, Short NJ, Ravandi F, Huang X, Daver N, DiNardo CD, Konopleva M, Pemmaraju N, Wierda W, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Khoury JD, Jorgensen J, Jain N, Alvarez J, O'Brien S, Kantarjian H.

Lancet Haematol. 2018 Dec;5(12):e618-e627. doi: 10.1016/S2352-3026(18)30176-5.

PMID:
30501869
6.

Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases.

Li JF, Dai YT, Lilljebjörn H, Shen SH, Cui BW, Bai L, Liu YF, Qian MX, Kubota Y, Kiyoi H, Matsumura I, Miyazaki Y, Olsson L, Tan AM, Ariffin H, Chen J, Takita J, Yasuda T, Mano H, Johansson B, Yang JJ, Yeoh AE, Hayakawa F, Chen Z, Pui CH, Fioretos T, Chen SJ, Huang JY.

Proc Natl Acad Sci U S A. 2018 Dec 11;115(50):E11711-E11720. doi: 10.1073/pnas.1814397115. Epub 2018 Nov 28.

7.

Ponatinib in the treatment of chronic myeloid leukemia and philadelphia chromosome positive acute lymphoblastic leukemia.

Pavlovsky C, Chan O, Talati C, Pinilla-Ibarz J.

Future Oncol. 2019 Jan;15(3):257-269. doi: 10.2217/fon-2018-0371. Epub 2018 Sep 25. Review.

PMID:
30251548
8.

A triple-probe FISH screening strategy for risk-stratified therapy of acute lymphoblastic leukaemia in low-resource settings.

Parihar M, Singh MK, Islam R, Saha D, Mishra DK, Saha V, Krishnan S.

Pediatr Blood Cancer. 2018 Dec;65(12):e27366. doi: 10.1002/pbc.27366. Epub 2018 Aug 31.

9.

Retrospective analysis of 36 fusion genes in 2479 Chinese patients of de novo acute lymphoblastic leukemia.

Chen X, Wang F, Zhang Y, Wang M, Tian W, Teng W, Ma X, Guo L, Fang J, Zhang Y, Zhu P, Liu H.

Leuk Res. 2018 Sep;72:99-104. doi: 10.1016/j.leukres.2018.08.009. Epub 2018 Aug 15.

PMID:
30125757
10.

Cooperative Enhancer Activation by TLX1 and STAT5 Drives Development of NUP214-ABL1/TLX1-Positive T Cell Acute Lymphoblastic Leukemia.

Vanden Bempt M, Demeyer S, Broux M, De Bie J, Bornschein S, Mentens N, Vandepoel R, Geerdens E, Radaelli E, Bornhauser BC, Kulozik AE, Meijerink JP, Bourquin JP, de Bock CE, Cools J.

Cancer Cell. 2018 Aug 13;34(2):271-285.e7. doi: 10.1016/j.ccell.2018.07.007.

11.

Updates in the Pathology of Precursor Lymphoid Neoplasms in the Revised Fourth Edition of the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues.

Wenzinger C, Williams E, Gru AA.

Curr Hematol Malig Rep. 2018 Aug;13(4):275-288. doi: 10.1007/s11899-018-0456-8. Review.

PMID:
29951888
12.

In vivo RNAi screening identifies Pafah1b3 as a target for combination therapy with TKIs in BCR-ABL1+ BCP-ALL.

Fiedler ERC, Bhutkar A, Lawler E, Besada R, Hemann MT.

Blood Adv. 2018 Jun 12;2(11):1229-1242. doi: 10.1182/bloodadvances.2017015610.

13.

A causal mechanism for childhood acute lymphoblastic leukaemia.

Greaves M.

Nat Rev Cancer. 2018 Aug;18(8):471-484. doi: 10.1038/s41568-018-0015-6. Review. Erratum in: Nat Rev Cancer. 2018 May 30;:.

PMID:
29784935
14.

Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: current treatments and future perspectives.

Yilmaz M, Kantarjian H, Ravandi-Kashani F, Short NJ, Jabbour E.

Clin Adv Hematol Oncol. 2018 Mar;16(3):216-223. Review.

PMID:
29742077
15.

New therapeutic opportunities from dissecting the pre-B leukemia bone marrow microenvironment.

Cheung LC, Tickner J, Hughes AM, Skut P, Howlett M, Foley B, Oommen J, Wells JE, He B, Singh S, Chua GA, Ford J, Mullighan CG, Kotecha RS, Kees UR.

Leukemia. 2018 Nov;32(11):2326-2338. doi: 10.1038/s41375-018-0144-7. Epub 2018 May 8.

16.

Two novel fusion genes, AIF1L-ETV6 and ABL1-AIF1L, result together with ETV6-ABL1 from a single chromosomal rearrangement in acute lymphoblastic leukemia with prenatal origin.

Lukes J Jr, Potuckova E, Sramkova L, Stary J, Starkova J, Trka J, Votava F, Zuna J, Zaliova M.

Genes Chromosomes Cancer. 2018 Sep;57(9):471-477. doi: 10.1002/gcc.6. Epub 2018 Jul 30.

PMID:
29726059
17.

Rapid identification of BCR/ABL1-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-polymerase chain reaction: clinical, prognostic and therapeutic implications.

Chiaretti S, Messina M, Grammatico S, Piciocchi A, Fedullo AL, Di Giacomo F, Peragine N, Gianfelici V, Lauretti A, Bareja R, Martelli MP, Vignetti M, Apicella V, Vitale A, Li LS, Salek C, Elemento O, Inghirami G, Weinstock DM, Guarini A, Foà R.

Br J Haematol. 2018 Jun;181(5):642-652. doi: 10.1111/bjh.15251. Epub 2018 Apr 19.

18.

Simultaneous detection of ABL1 mutation and IKZF1 deletion in Philadelphia chromosome-positive acute lymphoblastic leukemia using a customized target enrichment system panel.

Aoe M, Ishida H, Matsubara T, Karakawa S, Kawaguchi H, Fujiwara K, Kanamitsu K, Washio K, Okada K, Shibakura M, Shimada A.

Int J Lab Hematol. 2018 Aug;40(4):427-436. doi: 10.1111/ijlh.12805. Epub 2018 Mar 25.

PMID:
29575541
19.

Pre-B acute lymphoblastic leukaemia recurrent fusion, EP300-ZNF384, is associated with a distinct gene expression.

McClure BJ, Heatley SL, Kok CH, Sadras T, An J, Hughes TP, Lock RB, Yeung D, Sutton R, White DL.

Br J Cancer. 2018 Apr;118(7):1000-1004. doi: 10.1038/s41416-018-0022-0. Epub 2018 Mar 13.

20.

Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia.

Tran TH, Harris MH, Nguyen JV, Blonquist TM, Stevenson KE, Stonerock E, Asselin BL, Athale UH, Clavell LA, Cole PD, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Welch JJG, Reshmi SC, Neuberg DS, Sallan SE, Loh ML, Silverman LB.

Blood Adv. 2018 Mar 13;2(5):529-533. doi: 10.1182/bloodadvances.2017014704.

Supplemental Content

Loading ...
Support Center